Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide plus standard ADT in high-risk non-metastatic castration-resistant prostate cancer (China, phase II, single-arm)
CTR20212232Phase 2Completed
- Sponsor
- Bayer
- Start
- Sep 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of darolutamide in prostate cancer (PCa), sponsored by Bayer. Started Sep 2021; status: completed.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20212232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212232.